Related Experiment Video
Updated: Jul 19, 2025
09:26
Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro
Published on: June 6, 2025
301
Development of novel SARS-CoV-2 viral vectors
1Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, 250 West Green Street, Athens, GA, 30602, USA.
Scientific Reports
|August 11, 2023
Summary
Researchers developed a novel Venezuelan equine encephalitis virus (VEEV)-SARS-CoV-2 vector for safer research. This VEE-SARS-CoV-2 vector enhances gene expression and aids in developing antiviral therapies and diagnostics.
Area of Science:
- Virology
- Molecular Biology
- Biotechnology
Background:
- Authentic SARS-CoV-2 research is limited to Biosafety Level 3 laboratories.
- A need exists for safer, more accessible tools to study SARS-CoV-2.
Purpose of the Study:
- To develop a novel SARS-CoV-2 viral vector for enhanced research accessibility.
- To characterize the transduction efficiency and applications of the VEE-SARS-CoV-2 vector.
Main Methods:
- Constructed a VEEV-SARS-CoV-2 viral vector incorporating SARS-CoV-2 structural proteins, packaging signal, reporter gene, and VEEV RNA amplification.
- Assessed ACE2-dependent transduction and the necessity of SARS-CoV-2 structural proteins.
- Quantified gene expression levels and duration compared to standard vectors.
Main Results:
- The VEE-SARS-CoV-2 vector demonstrated ACE2-dependent transduction, requiring all four SARS-CoV-2 structural proteins.
- Incorporation of the VEEV self-amplification mechanism increased gene expression ~65-fold and extended expression to 11 days.
- The vector proved effective for neutralizing antibody quantification and antiviral drug screening.
Conclusions:
- The VEE-SARS-CoV-2 vector offers a versatile and safer tool for SARS-CoV-2 research.
- This vector facilitates studies on SARS-CoV-2 virology, antiviral development, and structural protein function.
